AVITA Medical's Cohealyx Study Shows 20-Day Reduction in Skin Grafting Time
Event summary
- Interim results from AVITA Medical's Cohealyx-I study show mean time to skin grafting reduced to 13.6 days vs. 33.2 days benchmark.
- Median time to grafting was 11 days, with some patients grafted as early as 5 days.
- Study ongoing with full dataset expected in 2026; 90% investigator satisfaction reported.
- Data to be presented at American Burn Association Annual Meeting and KOL webinar on April 16, 2026.
The big picture
AVITA Medical's positive interim results for Cohealyx highlight a significant advancement in wound care, potentially setting a new benchmark for time to skin grafting. The study's outcomes could position Cohealyx as a differentiated solution in the acute wound care market, addressing a key challenge in managing full-thickness wounds. The company's focus on integrating Cohealyx with its broader portfolio, including RECELL, underscores its strategy to optimize the entire wound healing pathway.
What we're watching
- Clinical Adoption
- Whether the 90% investigator satisfaction rate will translate into broader clinical adoption and market penetration.
- Regulatory Pathway
- The pace at which AVITA Medical can secure additional regulatory approvals for Cohealyx in key markets.
- Competitive Positioning
- How the 20-day reduction in grafting time will position Cohealyx against existing dermal matrices in the wound care market.
Related topics